Sanofi to acquire rights to develop, commercialize aficamten

Sanofi scoops up China rights to Cytokinetics’ heart disease med ahead of approval decision
As Cytokinetics’ aficamten awaits approval decisions from regulators in the U.S. and China, Sanofi has picked up China rights to the cardiovascular candidate. | As Cytokinetics’ aficamten awaits approval decisions from regulators in the U.
Sanofi To Buy Rights To Develop Cytokinetics' Aficamten In Greater China From Corxel
Cytokinetics, Inc.(CYTK), a late-stage, specialty cardiovascular biopharmaceutical company, Friday announced that French drug major
Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China
SOUTH SAN FRANCISCO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CYTK) today announced that Sanofi will acquire exclusive rights to develop and commercialize aficamten from Corxel Pharmaceuticals (CORXEL) for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) in Greater China.
Cytokinetics stock rises on Sanofi's rights acquisition
Investing.com -- Shares of Cytokinetics (NASDAQ: CYTK ), Incorporated (NASDAQ:CYTK) climbed 4.8% after the company announced that Sanofi (NASDAQ: SNY) will acquire exclusive rights to develop and commercialize aficamten in Greater China, a move that underscores the drug's potential in treating hypertrophic cardiomyopathy (HCM).
Cytokinetics, Incorporated: Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Sanofi will acquire exclusive rights to develop and commercialize aficamten
Sanofi to acquire rights to develop, commercialize aficamten from Corxel
Cytokinetics (CYTK) announced that Sanofi (SNY) will acquire exclusive rights to develop and commercialize aficamten from Corxel
Sanofi to buy China rights to Cytokinetics lead asset
Cytokinetics (NASDAQ:CYTK) announced Friday that Sanofi (NASDAQ:SNY) would buy exclusive rights to its lead candidate, aficamten, in Greater China from its partner, Corxel Pharmaceuticals. The company didn’t disclose the financial terms of the agreement between but said it remains on track to receive up to $150M in milestone payments and low-to-high teens on aficamten sales from the French drugmaker.
Why Cytokinetics Stock Was a Nearly 5% Winner Today
California-based biotech Cytokinetcs (NASDAQ: CYTK) finished the trading week in style, as its stock price outperformed many ...
STAT8d
Feds threaten Sanofi with sanctions over plan to change payment terms for a federal drug discount program
A U.S. government agency warned Sanofi that it faces sanctions over plans to change the way payments are made to most hospitals participating in a drug discount program, the second time in recent ...
pharmaphorum2d
Another big AI deal as Sanofi taps Exscientia for 15 new drugs
Shortly after Amgen unveiled its $1.9 billion alliance with Generate Biomedicines aimed initially at five drug molecules, Sanofi has announced a big expansion of its longstanding partnership with ...
Healthcare Dive5d
Sanofi sues HHS to defend 340B rebate policy
Drugmakers’ latest tactic is reforming how discounts are paid entirely. Earlier this year, J&J, Eli Lilly and Sanofi all tried to tweak how they divvy out 340B savings, by paying cash rebates ...
Teva Catapults 26%, Hitting A Six-Year High, After Scoring A Win With Sanofi-Tied Drug
Teva stock catapulted Tuesday after its inflammatory bowel disease treatment showed "best-in-class potential" in a Phase 2 ...